NP Theresa Stukus and NP Nelli Zafman discuss long-term management considerations for a patient with metastatic ...

The U.S. Food and Drug Administration (FDA) has expanded the approved indication for pirtobrutinib (Jaypirca) to include the ...

Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175. Most new prescriptions for specialty oral anticancer ...

At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton ...

An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology ...

September marks Gynecologic Cancer Awareness Month, an annual observation focused on increasing public and clinical awareness of gynecologic malignancies, including ovarian, endometrial, cervical, ...

Reverse thermal mitomycin gel now offers a chemoablative approach that provides prolonged mitomycin exposure to the bladder lining. The panel reviews results from the single-arm ENVISION trial, in ...

Commercialized by Lantheus Holdings, Inc., lutetium lu 177 dotatate (previously designated as PNT2003) represents the first ...

FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 ...

FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and ...

APHON 2026 speaker Amy C. Haskamp, CNS, discusses tiered self-care tactics and boundaries to help pediatric oncology nurses navigate emotional distress and burnout.

Solid tumor history, cardiopulmonary symptom burden, and age-dependent chemo intensity predicted 30-day readmission or death after AML induction. In a retrospective study published in JCO Clinical ...